This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of +2.52% and +1.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Labcorp Holdings (LH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
by Moumi Mondal
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Here's Why You Should Retain ICLR Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.
Icon PLC (ICLR) Down 9.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down
by Zacks Equity Research
ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.
Icon PLC (ICLR) Beats Q1 Earnings Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 3.57% and 0.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What to Expect From These 3 MedTech Stocks This Earnings Season?
by Zacks Equity Research
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Icon PLC (ICLR) Down 8.9% Since Last Earnings Report?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About ICON (ICLR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ICON (ICLR) stock based on the movements in the options market lately.
ICLR Q4 Earnings and Revenues Beat, Stock Rises at After-Market
by Zacks Equity Research
ICON's fourth-quarter 2024 earnings and revenues beat estimates as it manages to navigate a challenging transition period.
Icon PLC (ICLR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.29% and 0.29%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Icon PLC (ICLR) Q4 Earnings Expected to Decline
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 33.71% and 0.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 20th
by Zacks Equity Research
ICLR, BHP and CR have been added to the Zacks Rank #5 (Strong Sell) List on December 20, 2024.
New Strong Sell Stocks for December 10th
by Zacks Equity Research
BALY, ENPH and ICLR have been added to the Zacks Rank #5 (Strong Sell) List on December 10, 2024.
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls
by Zacks Equity Research
ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.
Icon PLC (ICLR) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of -12.99% and 5.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Icon PLC (ICLR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Implied Volatility Surging for ICON (ICLR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ICON (ICLR) stock based on the movements in the options market lately.